Compressed composite delivery system for release-rate modulation of bioactives

• US 20060024368A1
• Filed: 07/30/2004
• Published: 02/02/2006
• Est. Priority Date: 07/30/2004
• Status: Abandoned Application

• Current Assignee: Scolr Pharma Incorporated (Symrise AG)
• Original Assignee: Scolr Pharma Incorporated (Symrise AG)
• Inventors: Pillay, Viness, Fassihi, Reza
• Application Number:
  US10/903,267
• Publication Number:
  US 20060024368A1
• Time in Patent Office: Days
• US Class Current: 424/473
• CPC Class Codes: A61K 9/0065 Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer

Abstract

The invention is a delivery system comprising a first outer zone which partially surrounds an inner core, a second outer zone which also partially surrounds the core, and the outer zones together form a continuous heterogeneous layer fully surrounding the core. The delivery system is particularly suitable for orally administered multiple drug delivery or multiple rate delivery of biologically active ingredients to the gastrointestinal environment of humans or other animals.

Claims

1. A delivery system comprising a central core, a first outer zone, and a second outer zone in which:

the central core comprises one or more biologically active ingredients,

the first outer zone partially surrounds the core,

the second outer zone partially surrounds the core,

at least one of the first outer zone and the second outer zone comprises one or more biologically active ingredients, which one or more biologically active ingredients are the same as or different than the one or more biologically active ingredients in the core,

the first outer zone and the second outer zone are heterogeneous with respect to each other,

the first outer zone and the second outer zone together form a continuous layer completely enclosing the core,

the first outer zone comprises a barrier suitable for timed release of biologically active ingredients,

the second outer zone comprises a barrier suitable for timed release of biologically active ingredients, and

the core, the first outer zone, and the second outer zone together comprise a biologically effective dosage amount of each of the one or more biologically active ingredients.

2. The delivery system of claim 1 in which each of the first outer zone and the second outer zone independently releases any biologically active ingredient or ingredients contained in each zone and controls release of the active ingredient or ingredients present in the core.

3. The delivery system of claim 1 in which each of zones A and B delivers the active ingredient contained therein in different amounts, at different times, at different rates, or a combination thereof.

4. The delivery system of claim 1 in which one of the first outer zone and the second outer zone comprises at least sixty percent by weight of the combined weight of the first outer zone and the second outer zone.

5. The delivery system of claim 1 in which one of the first outer zone and the second outer zone surrounds the core to a greater extent than the other of the first outer zone and the second outer zone.

6. The delivery system of claim 1 in which the biologically active ingredient content of the first outer zone differs from the biologically active ingredient content of the second outer zone.

7. The delivery system of claim 1 in which one of the first outer zone and the second outer zone comprises a biologically active ingredient and the other of the first outer zone and the second outer zone does not comprise a biologically active ingredient.

8. The delivery system of claim 1 in which one of the first outer zone and the second outer zone comprises a first biologically active ingredient and the other of the first outer zone and the second outer zone comprises a second biologically active ingredient.

9. The delivery system of claim 1 in which the barrier of the first outer zone comprises at least one polymer and the barrier of the second outer zone comprises at least one polymer, and the first outer zone has a polymer content that differs from that of the second outer zone.

10. The delivery system of claim 1 in which the first outer zone and the second outer zone are present in a weight ratio of about 1:

10 to about 10;

1.

11. The delivery system of claim 1 in which the first outer zone and the second outer zone are present in a volume ratio of about 1:

10 to about 10;

1.

12. The delivery system of claim 1 in which the first outer zone and the second outer zone together comprise at least eight percent by weight to at least ninety-five percent by weight of the delivery system.

13. The delivery system of claim 1 in which the core is a compressed disk or tablet, a casted composite film, a laminate, an enteric coated tablet, an osmotically active tablet, a bilayer or triple layer tablet, or compressed granules, pellets or coated pellets.

14. The delivery system of claim 1 in which the core comprises about five percent to about ninety-two percent by weight of the delivery system.

15. The delivery system of claim 1 in which the core comprises from twenty-five percent to seventy-five percent by weight of the delivery system.

16. The delivery system of claim 1 in which the core, the first outer zone, and the second outer zone together comprise at least two biologically active ingredients, each of which is released over a time and at a rate which establishes or maintains at least the minimal therapeutic blood level for each active ingredient over an extended period of time in accordance with a scheduled dosage regimen.

17. A delivery system comprising a central core, a first outer zone, and a second outer zone;

in which;

the central core comprises one or more biologically active ingredients;

the first outer zone partially surrounds the core,

the second outer zone partially surrounds the core,

at least one of the first outer zone and the second outer zone comprises one or more biologically active ingredients, which one or more biologically active ingredients are the same as or different than the one or more biologically active ingredients in the core;

the first outer zone and the second outer zone are heterogeneous with respect to each other,

the first outer zone and the second outer zone together form a continuous layer completely enclosing the core,

the first outer zone comprises a barrier suitable for timed release of one or more biologically active ingredients;

the second outer zone comprises a barrier suitable for timed release of one or more biologically active ingredients;

either the barrier of the first outer zone or the barrier of the second outer zone, but not both, comprises a substantially non-erodable, swellable barrier that facilitates gastro-retentive properties of the delivery system; and

the core, the first outer zone, and the second outer zone together comprise a biologically effective dosage amount of each of the one or more biologically active ingredients;

18. The delivery system of claim 17 in which the outer zone that comprises the substantially non-erodable, swellable barrier additionally comprises a gas generating material.

19. The delivery system of claim 17 in which one of the first outer zone and the second outer zone comprises at least sixty percent by weight of the combined weight of the first outer zone and the second outer zone.

20. The delivery system of claim 17 in which one of the first outer zone and the second outer zone surrounds the core to a greater extent than the other of the first outer zone and the second outer zone.

21. The delivery system of claim 17 in which one of the first outer zone and the second outer zone comprises a biologically active ingredient and the other of the first outer zone and the second outer zone does not comprise a biologically active ingredient.

22. The delivery system of claim 17 in which the first outer zone and the second outer zone are present in a weight ratio of about 1:

10 to about 10;

1.

23. The delivery system of claim 17 in which the first outer zone and the second outer zone are present in a volume ratio of about 1:

10 to about 10;

1.

24. The delivery system of claim 17 in which the first outer zone and the second outer zone together comprise at least eight percent by weight to at least ninety-five percent by weight of the delivery system.

25. The delivery system of claim 17 in which the core is a compressed disk or tablet, a casted composite film, a laminate, an enteric coated tablet, an osmotically active tablet, a bilayer or triple layer tablet, or compressed granules, pellets or coated pellets.

26. The delivery system of claim 17 in which the core comprises about five percent by weight to about ninety-two percent by weight of the delivery system.

27. The delivery system of claim 17 in which the core comprises from twenty-five percent to seventy-five percent by weight of the delivery system.

28. The delivery system of claim 17 in which the core, the first outer zone, and the second outer zone together comprise at least two active ingredients, each of which is released over a time and at a rate which establishes or maintains at least the minimal therapeutic blood level for each active ingredient over an extended period of time in accordance with a scheduled dosage regimen.

29. A method for the controlled release of one or more biologically active ingredients, the method comprising administering a delivery system to an animal, the delivery system comprising a central core, a first outer zone, and a second outer zone,

in which:

the central core comprises one or more biologically active ingredients,

the first outer zone partially surrounds the core,

the second outer zone partially surrounds the core,

at least one of the first outer zone and the second outer zone comprises one or more biologically active ingredients, which one or more biologically active ingredients are the same as or different than the one or more biologically active ingredients in the core,

the first outer zone and the second outer zone are heterogeneous with respect to each other,

the first outer zone and the second outer zone together form a continuous layer completely enclosing the core,

the first outer zone comprises a barrier suitable for timed release of biologically active ingredients,

the second outer zone comprises a barrier suitable for timed release of biologically active ingredients, and

the core, the first outer zone, and the second outer zone together comprise a biologically effective dosage amount of each of the one or more biologically active ingredients.

30. The method of claim 29 in which the animal is a human.

31. The method of claim 30 in which at least one of the one or more biologically active ingredients is absorbed in the proximal intestine.

32. The method of claim 30 in which the one or more biologically active ingredients are selected from the group consisting of ciproflox, metformine, cyclosporine, doxiflurodine, iron salts, ampicillen, ketoconazole, micoconozole, and combinations thereof.

33. The method of claim 30 in which at least one of the one or more biologically active ingredients has high solubility in an acidic environment.

34. The method of claim 30 in which the one or more biologically active ingredients are selected from the group consisting of propranolol, metoprolol, diltiazem, verapamil, theophylline, paracetamol, pseudoephedrine sulfate, metformin hydrochloride, danazol, mefenamic acid, nisoldipine, nifedipine, nicardipine, felodipine, atovaquone, griseofulvin, troglitazone, glibenclamide, carbamazepine, acyclovir, neomycin B, captopril, enalaprilate, alendronate, atenolol, cimetidine, ranitidine, Methydopa, timolol succinate and maleate,sulindac, losartan salts, indinavir sulfate, metyrosine, chlorthiazide, diflunisal, alendronate salts, lovastatin, thiabendazol, norfloxacin, montelukast salts, trientine salts, procainamide, hydoxyurea, atrovastatin, gabapentin, gemfibrozil, fluconazole, trovafloxacin salts, doxepin salt, dofetilide, sertraline salt, sulfasalazine, etidronate disodium, morphine sulfate, oxycodone hydrochloride and sulphate, choline magnesium trisalicylate, quinidine sulfate, ganciclovir, methocarbamol, aspirin,saquinavir, valganciclovir, colesevelam, tolcapone, capecitabine, ortistat, irbesartan, succimer, loratadine, pseudoephedrineflutamide, labetalolo, zolpidem tartarate, celecoxib, pancrelipase, soprolol, etodolac, disulfiram, amiodaron, venlafaxine hydrochloride, hydrochlorothiazide, acebutolol, glucosamine, propoxyphene, raloxifene salt, fluoxetine, cefuroxime axetil, cefixime, abacavir sulfate, bupropion, zidovudine, lamivudine, chlorpromazine, amoxicillin, clavulanate potassium, amprenavir, sevelamer hydrochloride, carbidopa, levodopa, glyburide, gatifloxacin, cefadroxil monohydrate, quinidine gluconate, sotalolo, methenamine mandelate, moxifloxacin salts, praziquantel, quetiapine fumarate, tocainide hydrochloride and other salts, clarithromycin, divalproex sodium, erythromycin, lopinavir, ritonavir, propafenone, and combinations thereof.

35. The method of claim 30 in which the one or more biologically active ingredients are selected from the group consisting of peptides, proteins, and combinations thereof.

36. The method of claim 30 in which the core, the first outer zone, and the second outer zone together comprise at least two biologically active ingredients, each of which is released over a time and at a rate which establishes or maintains at least the minimal therapeutic blood level for each active ingredient over an extended period of time in accordance with a scheduled dosage regimen.